Utilising CNC’s core technology and ECOpure proprietary liquids, our team has been developing a new variant inhalation device which will exist under the medicines regulatory framework as a smoking cessation device/drug.

The product is now in final prototype stage, with clinical studies expected to be conducted early in 2012, and a Marketing Authorisation application scheduled for the summer of 2012.

A new microsite will be launched in the near future with updates on our development path.